European journal of preventive cardiology最新文献

{"title":"Effects of exercise training on nitric oxide metabolites in heart failure with reduced or preserved ejection fraction: a secondary analysis of the SMARTEX-HF and OptimEx-Clin trials.","authors":"Sophia Marie-Theres Dinges, Edzard Schwedhelm, Julia Schoenfeld, Andreas B Gevaert, Ephraim B Winzer, Bernhard Haller, Flavia Baldassarri, Axel Pressler, André Duvinage, Rainer Böger, Axel Linke, Volker Adams, Burkert Pieske, Frank Edelmann, Håvard Dalen, Torstein Hole, Alf Inge Larsen, Patrick Feiereisen, Trine Karlsen, Eva Prescott, Øyvind Ellingsen, Emeline M Van Craenenbroeck, Martin Halle, Stephan Mueller","doi":"10.1093/eurjpc/zwaf142","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf142","url":null,"abstract":"<p><strong>Aims: </strong>Exercise has been shown to affect the nitric oxide (NO) pathway, which is involved in the pathophysiology of endothelial dysfunction in heart failure (HF) with reduced (HFrEF) and preserved ejection fraction (HFpEF). However, the effects of different exercise modes on NO metabolites in patients with HF are uncertain.</p><p><strong>Methods: </strong>Blood samples from two randomized controlled HF trials evaluating 1.) high-intensity-interval-training (HIIT), 2.) moderate-continuous-training (MCT) or 3.) a control group (CG) in HFrEF (SMARTEX-HF) and HFpEF (OptimEx-Clin) were analysed for NO metabolites L-arginine, homoarginine (hArg), asymmetric and symmetric dimethylarginine (ADMA; SDMA). Metabolite plasma concentrations were compared between HFrEF and HFpEF at baseline and within each HF type after 3 months of supervised exercise training and 12 month-follow-up.</p><p><strong>Results: </strong>Overall, 206 patients with HFrEF (61±12 years, 18.9% females) and 160 with HFpEF (70±8 years, 65.6% females) were investigated. Baseline hArg (1.74±0.78 vs. 1.31±0.69 µmol/l) and ADMA (0.68±0.15 vs. 0.62±0.09 µmol/l) were significantly higher in HFrEF (p<0.001). NO metabolites showed several significant associations with markers of HF severity like exercise capacity (VO2peak) and NT-proBNP, but not with measures of endothelial function (reactive hyperaemia index, flow-mediated dilation). After 3 months of exercise and 12-month-follow-up, changes in metabolite plasma levels were not significantly different between study groups (HIIT, MCT or CG) (pgroup*time >0.05), neither in HFrEF nor HFpEF.</p><p><strong>Conclusion: </strong>Baseline NO metabolite profile was unfavourable in patients with HF and lower VO2peak or higher NT-proBNP. We did not find a significant influence of HIIT or MCT on NO metabolites at 3 and 12 months.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine mitigates arterial stiffness in high-risk patients with type 2 diabetes: A randomized placebo-controlled trial.","authors":"Jonathan M Baier, Kristian L Funck, Liv Vernstrøm, Søren Gullaksen, Esben Laugesen, Per L Poulsen","doi":"10.1093/eurjpc/zwaf143","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf143","url":null,"abstract":"<p><strong>Aims: </strong>The anti-inflammatory drug colchicine has been shown to reduce the risk of cardiovascular disease in patients with and without diabetes. The underlying mechanisms are, however, elusive. In this trial, we investigated the effect of colchicine on arterial stiffness, ambulatory blood pressure, and albuminuria in patients with type 2 diabetes.</p><p><strong>Methods: </strong>We conducted a double-blind, randomized, placebo-controlled trial in individuals with type 2 diabetes with a history of cardiovascular disease or a high risk hereof. One hundred participants were assigned in a 1:1 ratio to receive colchicine 0.5 mg once daily or placebo for 26 weeks. The primary outcome was change in arterial stiffness assessed as carotid-femoral pulse wave velocity (cfPWV). Secondary outcomes included 24-hour ambulatory BP and urine albumin-to-creatinine ratio (UACR).</p><p><strong>Results: </strong>Treatment with colchicine significantly mitigated arterial stiffness progression compared to placebo (mean arterial pressure (MAP)-adjusted change in cfPWV: -0.7 m/s, 95% CI: -1.3; -0.1, p = 0.03). Crude analyses without MAP-adjustment showed a non-significant reduction in cfPWV of -0.3 m/s (95% CI: -1.0;0.4, p = 0.45). Colchicine had no significant effect on 24-hour systolic ambulatory BP (change: 3.0 mmHg, 95% CI: -0.5;6.5 mmHg, p = 0.10) or UACR (percentage change: 0.5, 95% CI: -29.5;40.4, p = 0.98).</p><p><strong>Conclusion: </strong>This study suggests that low-dose colchicine may reduce arterial stiffness in high-risk patients with type 2 diabetes. While these findings indicate that mitigating arterial stiffness contribute to the observed reduction in cardiovascular events in outcome trials, further research is needed to confirm these effects and understand the underlying mechanisms.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"It's always the cardiovascular inflammation! Even due to food….","authors":"Giuseppe Biondi-Zoccai, Marco Bernardi, Elena Tremoli","doi":"10.1093/eurjpc/zwaf141","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf141","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology.","authors":"Maurizio Volterrani, Geza Halasz, Stamatis Adamopoulos, Pier Giuseppe Agostoni, Javed Butler, Andrew J S Coats, Alan Cohen-Solal, Wolfram Doehner, Gerasimos Filippatos, Ewa Jankowska, Carolyn S P Lam, Ekaterini Lambrinou, Lars H Lund, Giuseppe Rosano, Marco Metra, Stefania Paolillo, Pasquale Perrone Filardi, Amina Rakisheva, Gianluigi Savarese, Petar Seferovic, Carlo Gabriele Tocchetti, Massimo Piepoli","doi":"10.1093/eurjpc/zwad400","DOIUrl":"https://doi.org/10.1093/eurjpc/zwad400","url":null,"abstract":"<p><p>For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a range of physical and psychological symptoms, including shortness of breath, chest discomfort, fatigue, fluid congestion, trouble with sleeping, and depression. These symptoms reduce patients' capacity for daily social and physical activity. Usual endpoints of large-scale trials in chronic HF have mostly been defined to evaluate treatments regarding hospitalizations and mortality, but more recently, patients' priorities and needs expressed with QoL are gaining more awareness and are being more extensively evaluated. This scientific statement aims at discussing the importance of QoL in HF, summarizing the most largely adopted questionnaires in HF care, and providing an overview on their application in trials and the potential for their transition to clinical practice. Finally, by discussing the reasons limiting their application in daily clinical routine and the strategies that may promote their implementation, this statement aims at fostering the systematic integration of the patient's standpoint in HF care.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease.","authors":"Kyuwoong Kim, Minkyoung Kim, Jiye Han, Hyeyun Jung, Ah-Ram Kim, Tae Joon Jun, Young-Hak Kim","doi":"10.1093/eurjpc/zwaf036","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf036","url":null,"abstract":"<p><strong>Aims: </strong>Lipoprotein(a) [Lp(a)] is an emerging risk factor for major adverse cardiovascular events (MACE). However, evidence on MACE risk according to Lp(a) level in atherosclerotic patients is insufficient, and more data is needed about whether type 2 diabetes (T2DM) additionally contributes to this risk. We aimed to investigate the association between Lp(a) and MACE in atherosclerotic patients and compare the magnitude of Lp(a)-MACE association in the patients with and without T2DM.</p><p><strong>Methods and results: </strong>Using a retrospective cohort study of atherosclerotic patients with and without T2DM who were screened for Lp(a) between 1 January 2000 to 31 December 2020, we estimated the risk of MACE according to Lp(a) level stratified by quintiles and compared the difference in magnitude of Lp(a)-MACE association according to presence of T2DM with partial likelihood ratio test. The study included 25 826 patients with established atherosclerotic cardiovascular disease, of whom 7535 had T2DM (29.2%) and 18 291 did not (70.8%). During 160 174 person-years (PY) of follow-up, a total of 4836 MACE were observed. Compared to the lowest quintile (Q) of Lp(a) levels, multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for MACEs across Q2 to Q5 were 1.10 (95% CI: 0.94-1.30), 0.98 (95% CI: 0.83-1.16), and 1.25 (95% CI: 1.06-1.46), 1.29 (95% CI: 1.10-1.51) in patients with T2DM, and 0.99 (95% CI: 0.88-1.12), 1.10 (95% CI: 0.98-1.23), 1.01 (95% CI: 0.90-1.13), and 1.13 (95% CI: 1.01-1.27) for those without T2DM. The strength of Lp(a)-MACE association was stronger among the patients with T2DM (P < 0.001).</p><p><strong>Conclusion: </strong>Among atherosclerotic patients with and without T2DM, elevated Lp(a) level was significantly associated with a higher risk of MACE. Compared to those without T2DM, the patients with T2DM showed an excess MACE risk, suggesting the need for clinical interventions concerning both Lp(a) level and glycemic control.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apolipoprotein C3, triglycerides, and cardiovascular risk in optimally treated ACS patients: The critical role of mediation analysis and implications for precision primary prevention: Reply.","authors":"Gregory G Schwartz, Michael Szarek, Philippe Gabriel Steg","doi":"10.1093/eurjpc/zwaf136","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf136","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific cardiovascular disease risk prediction using statistical learning and explainable artificial intelligence: the HUNT Study.","authors":"Virginia De Martin Topranin, Atle Wiig-Fisketjøn, Emma Botten, Håvard Dalen, Mette Langaas, Anja Bye","doi":"10.1093/eurjpc/zwaf135","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf135","url":null,"abstract":"<p><strong>Aims: </strong>Current risk prediction models, such as the Norwegian NORRISK 2, explain only a modest proportion of cardiovascular disease (CVD) incidence. This study aimed to develop improved sex-specific models for predicting the 10-year CVD risk as well as sex- and age-specific thresholds for intervention.</p><p><strong>Methods: </strong>Data from 31,946 participants (40-79 years) without prior CVD were analyzed. Data were randomly split into a training set (for estimation) and a test set (for model evaluation). An extreme gradient boosting (XGBoost) model was used to identify the most important predictive variables. Next, prediction models were developed on the training set for each sex separately using XGBoost and logistic regression. The models were evaluated on the test set using receiver-operating characteristic (ROC) and precision recall (PR) curves. Finally, age- and sex-specific thresholds for intervention were explored.</p><p><strong>Results: </strong>All traditional risk factors included in NORRISK 2 and the European SCORE2 model were important predictors for males, but not for females. Potential new risk predictors were identified. The XGBoost model improved CVD risk prediction for males: 0.013- and 0.012-unit increase in ROC-AUC compared to NORRISK 2 and SCORE2 respectively, and 12% and 11% increase in PR-AUC respectively. For females, neither the XGBoost nor logistic regression model performed significantly better than NORRISK 2 and SCORE2. Age- and sex-specific thresholds showed an improvement in sensitivity compared with NORRISK 2-suggested thresholds.</p><p><strong>Conclusions: </strong>By employing statistical learning and incorporating sex-specific risk factors, we propose improved risk prediction models for CVD in males. Introducing sex-specific thresholds for intervention could enhance CVD prevention for both sexes.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: EJPC Reviewers 2024.","authors":"","doi":"10.1093/eurjpc/zwaf132","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf132","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing Clinical Considerations of Abdominal Obesity, Non-Fasting Triglycerides, and Cardiovascular Risk.","authors":"Malene Revsbech Christiansen, Germán D Carrasquilla, Tuomas O Kilpeläinen","doi":"10.1093/eurjpc/zwaf134","DOIUrl":"10.1093/eurjpc/zwaf134","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of asymptomatic atrial fibrillation and risk factors associated with asymptomatic status: a systematic review and meta-analysis.","authors":"Konstantinos Pamporis, Paschalis Karakasis, Marios Sagris, Panagiotis Theofilis, Nikias Milaras, Antonia Pantelidaki, Iordanis Mourouzis, Nikolaos Fragakis, Konstantinos Vlachos, Athanasios Kordalis, Dimitrios Tsiachris","doi":"10.1093/eurjpc/zwaf138","DOIUrl":"10.1093/eurjpc/zwaf138","url":null,"abstract":"<p><strong>Aim: </strong>Asymptomatic atrial fibrillation (AF) is frequent and associated with disease progression. This meta-analysis aimed to estimate the prevalence of asymptomatic AF and identify risk factors associated with asymptomatic status.</p><p><strong>Methods: </strong>MEDLINE(Pubmed), Scopus, Cochrane and ClinicalTrials.gov were searched until January 8, 2025. Double-independent study selection, data extraction and quality assessments were performed. Random-effects meta-analysis was used. Estimates are presented with the asymptomatic individuals in the nominator and the symptomatic patients in the denominator. The assessment of the prevalence of asymptomatic AF and the identification of risk factors associated with the asymptomatic status comprised the main endpoints.</p><p><strong>Results: </strong>Thirty-seven studies (224273 participants) were included. The prevalence of asymptomatic AF was 27% (95% confidence interval {CI}=[22%,33%]; I2=100%). Risk factors positively associated with the asymptomatic status were male sex (odds ratio {OR}=1.67, 95%CI=[1.48,1.89], p<0.001, I2=85%), diabetes mellitus (OR=1.19, 95%CI=[1.07,1.33], p=0.002, I2=87%), chronic kidney disease (OR=1.21, 95%CI=[1.08,1.36], p<0.001, I2=80%) and stroke/transient ischemic attack (OR=1.43, 95%CI=[1.18,1.73], p<0.001, I2=95%), while heart failure was negatively associated with asymptomatic AF (OR=0.71, 95%CI=[0.54,0.94], p=0.017, I2=97%). Asymptomatic status was also positively associated with permanent AF (OR=2.13, 95%CI=[1.28,3.55]; p=0.004; I2=98%) and negatively associated with catheter ablation (OR=0.63, 95%CI=[0.44,0.91]; p=0.012; I2=95%), beta-blockers (OR=0.90, 95%CI=[0.82,0.98]; p=0.018; I2=68%) and antiarrhythmics (OR=0.53, 95%CI=[0.35,0.79]; p=0.002; I2=95%).</p><p><strong>Conclusions: </strong>Asymptomatic AF was estimated around 27%, with large variability depending on the prevalence of risk factors associated with asymptomatic status. Asymptomatic individuals had distinct characteristics compared to symptomatic patients, regardless of symptoms' assessment methods and rhythm/rate control interventions. Our results could inform AF screening practices to target asymptomatic individuals.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}